AFP and hepatocellular carcinoma: All Eastern guidelines recommend a 6-monthly US as the first-line imaging modality for HCC screening/surveillance in high-risk groups [1–4], with additional recommendations on serum alfa-fetoprotein (AFP) measurement in the APASL, KLCA-NCC, and CNLC guidelines [1, 2, 4].